
    
      This is a double-blind, randomized, placebo-controlled, cross-over study in subjects with
      Lewy body dementia who experience frequent visual hallucinations.

      Subjects who meet the randomization criteria enter the double-blind treatment period.

      Each subject will be randomized 1:1 to one of the 2 treatment sequences: Nelotanserin in the
      first treatment period followed by placebo in the second treatment period, or placebo in the
      first treatment period followed by Nelotanserin in the second treatment period.
    
  